Stavroula Kousteni, PhD

“The TRx program gave us access to expertise and the opportunity to establish connections with a group of faculty that could readily provide advice and access to resources to successfully design and perform essential parts of the project,” Dr. Kousteni says.

“Remarkably, these advantages gave us the opportunity to assess an additional biological endpoint that was not planned originally in the application because at the time of submission, I did not believe we would have adequate funds and expertise to afford it.”

These additional experiments yielded results with significant translational value and therapeutic potential. “The results obtained have strengthened the notion that LCN2 can be a therapeutically relevant molecule in the treatment of obesity,” she says. “We plan to explore the translational potential of LCN2 by presenting this work to interested investors and companies.”